News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Articles|April 22, 2020

COVID-19 Quick Clip: Access to Care

Author(s)Deena J. Tampi, MSN, MBA-HCA, RN, DFAAGP

Behavioral health care providers are needed now more than ever to help support frontline caregivers and to provide access to care. Deena Tampi, MSN, MBA-HCA, offers insights about caring for the caregiver as well as providing access to care.

Behavioral health care providers are needed now more than ever to help support frontline caregivers and to provide access to care. Deena Tampi, MSN, MBA-HCA, offers insights about caring for the caregiver as well as providing access to care.

Ms Tampi is Executive Vice President, Diamond Healthcare, Richmond, VA, where she uses her evidence-based expertise to ensure accountable care in behavioral health, ethics, and geriatric psychiatry.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

LSD generalized anxiety recent study

LSD for Generalized Anxiety Disorder: New Findings Review With Maurizio Fava, MD

ByMaurizio Fava, MD

October 8th 2025

Endocannabinoid System

SYT-510: First-in-Class Inhibitor Targets Endocannabinoid System to Improve Mental Health Outcomes

September 24th 2025

lumateprone caplyta major depressive disorder anxious distress

Phase 3 Study of Lumateperone as Adjunct to Antidepressant Therapy for Major Depressive Disorder and Anxious Distress Meets End Points

ByJessica Walters

September 21st 2025

cannabidiol CBD crystal

New Preclinical Data on ART12.11 for the Treatment of Mood and Anxiety Disorders

September 10th 2025

Target Enrollment Completed for Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder

September 4th 2025

Latest CME

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

Ilan Melnick, MD; Alejandro Alva, MD; Linda Trinh, DNP, PMHNP, FNP, MPH

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

Sanjai Rao, MD, DFAPA; Dawn I. Velligan, PhD

Southern Florida Psychiatry Conference

In-Person Event

Southern Florida Psychiatry Conference

November 21-22, 2025

Real Psychiatry 2026

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Optimizing Care for Patients With Tardive Dyskinesia

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

(CME Track) Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

(CME Track) Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CME Track) Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(Pharmacist Track) Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(Pharmacist Track) Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

(Pharmacist Track) Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

Can the Initial Antipsychotic Influence Years of Weight Gain?

Evidence-Based Psychotherapy and Psychopharmacology for Mood Disorders: A Conversation With Holly A. Swartz, MD

New Post-Hoc Analysis: Ingrezza 40 mg Leads to Clinically Meaningful Improvements in Tardive Dyskinesia Symptoms

How to Approach Conversations With Adult Patients Who Might Have ADHD: New Tools and Insights

Loneliness, Meet Solitude

© 2025 MJH Life Sciences^®

All rights reserved.